Heparin-induced thrombocytopenia paradoxically is a transient pro-thrombotic disorder triggered by heparin exposure. If not treated appropriately, it can be life threatening because of its related thromboembolic complications. In particular, it presents a unique challenge in patients needing extracorporeal life support, because anticoagulation is essential for safe management. This case report describes the safe, efficacious use of Argatroban during short-term support of a patient with a percutaneously inserted left ventricular assist TandemHeart device.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680635 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Short-term Functional Outcomes and Treatment Trends between Branch Atheromatous Disease and Lacunar Infarction: Retrospective Cohort Study of the Nationwide Multicenter Registry.
Clin Exp Emerg Med
July 2024
Department of Neurology, Saiseikai Shiga Hospital, Imperial Gift Foundation Inc., Shiga, Japan.
Background: Branch atheromatous disease (BAD) is a form of ischemic stroke that presents with imaging findings similar to those of lacunar infarction, but has a different pathogenesis and is known to cause progressive paralysis. Due to regional variations, the epidemiology of BAD is not wellunderstood, and its relationship with functional prognosis remains unclear. Using a comprehensive Japanese stroke database, we investigated its epidemiological characteristics and associations with functional outcomes.
View Article and Find Full Text PDFThe effect of argatroban on early neurological deterioration and outcomes in minor ischemic stroke: preliminary findings.
Front Neurol
March 2024
Department of Neurology, Suzhou Ninth People's Hospital, Soochow University, Suzhou, China.
Background: Minor ischemic stroke (MIS) is associated with early neurological deterioration (END) and poor prognosis. Here, we investigated whether argatroban administration can mitigate MIS-associated END and improve functional outcomes by monitoring activated partial thrombin time (APTT).
Methods: Data were collected for patients with MIS admitted to our hospital from January 2019 to December 2022.
Efficacy and safety of Agatroban in improving the prognosis of ischemic stroke patients.
Am J Transl Res
September 2023
Internal Medicine-Neurology, Shanghai Songjiang Sijing Hospital Shanghai 201601, China.
Objective: To explore and analyze the efficacy and safety of combined treatment of Agatroban and Aspirin in improving short-term and long-term prognosis of ischemic stroke patients.
Methods: In this retrospective study, the clinical data of patients with ischemic stroke admitted to the Department of Neurology, Songjiang Sijing Hospital from June 2021 to April 2023 were analyzed. A total of 108 patients were selected according to the inclusion and exclusion criteria, including 54 patients treated with Aspirin only, named the control group, and 54 patients treated with Agatroban plus Aspirin, named the study group.
Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis.
Brain Behav
July 2022
Department of Neurology, General Hospital of Northern Theater Command, Shenyang, P.R. China.
Objective: Previous studies suggest the benefit of dual antiplatelet therapy (DAPT) for acute ischemic stroke with large artery atherosclerosis (LAA) etiology, but there is no study about the effect of DAPT plus anticoagulant in this population.
Methods: A prospective single arm trial was performed to determine the effect of DAPT combined with argatroban on acute mild to moderate ischemic stroke patients with LAA, which was compared with historical populations. The main outcome was the proportion of early neurological deterioration (END).
Effect of Argatroban Combined With Dual Antiplatelet Therapy on Early Neurological Deterioration in Acute Minor Posterior Circulation Ischemic Stroke.
Clin Appl Thromb Hemost
October 2020
Department of Neurology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
There is a lack of studies on anticoagulant plus antiplatelet therapy for acute ischemic stroke. The present study made a pilot effort to investigate the efficacy and safety of argatroban plus dual antiplatelet therapy (DAPT) in patients with acute posterior circulation ischemic stroke (PCIS). We retrospectively collected patients diagnosed with acute PCIS according to inclusion/exclusion criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!